Epidemiological study of Hepatitis C in people deprived of liberty
Main Article Content
Abstract
Introduction: The prevalence of hepatitis C (HCV) is high among prisoners. If untreated, a substantial number of patients progress to cirrhosis, hepatocarcinoma, or liver failure. World Health Organization aims to reduce the incidence of infection by 90% by 2030. Objective: To describe the prevalence of anti-HCV and sociodemographic and clinical aspects, related to the presence of the antibody, in the population deprived of liberty. Methods: Cross-sectional and epidemiological survey, with exploratory, observational, quantitative-analytical components. A simple random sample of 233 participants, with 95% Confidence Interval (CI) and, a 4% margin of error, was calculated for a population of 1,564 prisoners. The relationship between sociodemographic and clinical variables was evaluated, considering as outcome of the rapid test for anti-HCV results, using the associative measure Prevalence Ratio (PR) with a 95% CI. Results: 240 people participated. The prevalence of anti-HCV was 2%, and the use of injectable drugs (PR 14.75; PRIC95% 2.09-104.28), being born in the decades of 1951 to 1980 (PR 9.28; PRIC95% 1.06-81.57) and be co-infected with hepatitis B virus (PR 10.75; PRIC95% 1.66-69.65) were the aspects that presented a relevant prevalence ratio for the presence of the virus, which could be generalized to the population. Conclusion: This is a population that is difficult to access, the study is relevant because it contributes to preventive measures of public health in the prison system. Moreover, it shows the need to implement measures to prevent and contain the spread of HCV, aiming at the elimination of hepatitis C in this population.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY) that allows others to share and adapt the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.References
Akiyama MJ. Hepatitis C in the criminal justice system: opportunities for global action in the era of viral hepatitis elimination. BMC Med. 2020;18(1):208. https://doi.org/10.1186/s12916-020-01680-0
Snow KJ, Richards AH, Kinner SA. Use of multiple data sources to estimate hepatitis C seroprevalence among prisoners: A retrospective cohort study. Plos One. 2017;12(7):e0180646. https://doi.org/10.1371/journal.pone.0180646
Akiyama MJ, Ross J, Rimawi F, Fox A, Jordan AO, Wiersema J, et al. Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study. Plos One. 2020;15(12):e0242623. https://doi.org/10.1371/journal.pone.0242623
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932-54. https://doi.org/10.1002/hep.27950
AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infec Dis. 2018;67(10):1477-92. https://doi.org/10.1093/cid/ciy585
Puga MAM, Bandeira LM, Pompilio MA, Croda J, Rezende GR, Dorisbor LFP, et al. Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil. Plos One. 2017;12(1):e0169195. https://doi.org/10.1371/journal.pone.0169195
Queiroz IT, Couras S, Cabral D. Micro-elimination of hepatitis c in the incarcerated population: is it really possible? Arq Gastroenterol. 2021;58(3):399-401. https://doi.org/10.1590/S0004-2803.202100000-67
Araújo TME, Pinheiro DM, Souza ATS. Hepatitis C and associated risks in prisons: an integrative review. Rev Pesq Cuidado Fund Online. 2017;9(4):939-45. https://doi.org/10.9789/2175-5361.2017.v9i4.939-945
Gomide GPM, Teixeira MS, Pereira GA, Camargo FC, Pastori BG, Dias FF, et al. Experience in the management of action research on hepatitis C investigation with the prison community. Cienc Saude Coletiva. 2022;27(12):4389-96. https://doi.org/10.1590/1413-812320222712.08742022
Magri MC, Ibrahim KY, Pinto WP, França FO, Bernardo WM, Tengan FM. Prevalence of hepatitis C virus in Brazil's inmate population: a systematic review. Rev Saude Publica. 2015;49:36. https://doi.org/10.1590/S0034-8910.2015049005886
Coêlho HC. Presença dos vírus HBV e HCV e seus fatores de riscos nos presidiários masculinos da penitenciária de Ribeirão Preto. [Dissertation]. [Ribeirão Preto]: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 2008.
Gomide GPM, Melo CB, Santos VS, Salge VD, Camargo FC, Pereira GA, et al. Epidemiological survey of hepatitis C in a region considered to have high prevalence: the state of Minas Gerais, Brazil. Rev Soc Bras Med Trop. 2019;52:e20190202. https://doi.org/10.1590/0037-8682-0202-2019
Winter RJ, Holmes JA, Tj Papaluca, AJ Thompson. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14(3):497. https://doi.org/10.3390/v14030497
Gomide GPM, Molina RJ, Pereira GA, Oliveira CCHB. Early diagnosis of hepatitis C by primary health care. REFACS. 2021;9(Supl. 1):271-81. https://doi.org/10.18554/refacs.v9i0.4242
Airewele NE, Shiffman ML. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. Clin Liver Dis. 2021;25(4):817-29. https://doi.org/10.1016/j.cld.2021.06.008
Viola L, Marciano S, Colombato L, Coelho H, Cheinquer H, Bugarin G, et al. HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America. Ann Hepatol. 2020;19(2):161-5. https://doi.org/10.1016/j.aohep.2019.09.006
Alonso M, Gutzman A, Mazin R, Pinzon CE, Reveiz L, Ghidinelli M. Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health. 2015;60(7):789-98. https://doi.org/10.1007/s00038-015-0708-5
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Global Health. 2017;5(12):e1192-e207. https://doi.org/10.1016/S2214-109X(17)30375-3
Boelen L, Teutsch S, Wilson DP, Dolan K, Dore GJ, Lloyd AR, et al. Per-event probability of hepatitis C infection during sharing of injecting equipment. Plos One. 2014;9(7):e100749. https://doi.org/10.1371/journal.pone.0100749
Nakitanda AO, Montanari L, Tavoschi L, Mozalevskis A, Duffell E. Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action. BMC Public Health. 2020;20(1):1670. https://doi.org/10.1186/s12889-020-09515-6
Werling K, Hunyady B, Makara M, Nemesi K, Horváth G, Schneider F, et al. Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents. Viruses. 2022;14(2):308. https://doi.org/10.3390/v14020308
Belaunzarán-Zamudio PF, Mosqueda-Gomez JL, Macias-Hernandez A, Sierra-Madero JG, Ahmed S, Beyer C. Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico. Plos One. 2017;12(6):e0179931. https://doi.org/10.1371/journal.pone.0179931
Guimarães T, Granato CF, Varella D, Ferraz ML, Castle A, Kallás EG. High prevalence of hepatitis C infection in a Brazilian prison: identification of risk factors for infection. Braz J Infect Dis. 2001;5(3):111-8. https://doi.org/10.1590/s1413-86702001000300002
Gonçalves K. Life history and health situation in the prison environment of Goiás: study of the prevalence of hepatitis C in inmates [Dissertation]. [Goiânia]: Universidade Católica de Goiás, 2005.
Rosa F, Carneiro M, Duro LN, Valim ARM, Reuter CP, Burgos MS, et al. Prevalence of anti-HCV in an inmate population. Rev Assoc Med Bras. 2012;58(5):557-60. https://doi.org/10.1590/S0104-42302012000500012
Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C Screening of the "Birth Cohort" (Born 1945-1965) and Younger Inmates of New York City Jails. Am J Public Health. 2016;106(7):1276-7. https://doi.org/10.2105/AJPH.2016.303163
Oliveira AC, Bortotti AC, Nunes NN, El Bacha IAH, Parise ER. Association between age at diagnosis and degree of liver injury in hepatitis C. Braz J Infect Dis. 2014;18(5):507-11. https://doi.org/10.1016/j.bjid.2014.04.003
Busschots D, Kremer C, Bielen R, Koc OM, Heyens L, Brixko C, et al. A multicentre interventional study to assess blood-borne viral infections in Belgian prisons. BMC Infect Dis. 2021;708. https://doi.org/10.1186/s12879-021-06405-z
Mohtasham-Amiri Z, Rezvani SM, Ashoori F, Behboodi M, Toosi H, Jafari-Shakib R. Seroprevalence of Hepatitis C Virus among Prisoners in Lakan Prison, North of Iran, Is There Still a Concern? Arch Iran Med. 2021;24(10):765-70. https://doi.org/10.34172/aim.2021.113
Tejera-Pérez RJ, Iglesias-Gómez A, Oliva-Oliva A, Rodríguez-Alonso B, Alonso-Sardón M, Ledesma MS, et al. Real-life experience of hepatitis C treatment in a Spanish prison. Rev Esp Chemioter. 2022;35(3):273-8. https://doi.org/10.37201/req/001.2022